- Published on
Infectious Disease and Microbiology - Measles
Measles is a highly contagious viral disease characterized by fever and a distinctive maculopapular rash that begins on the face and spreads downward to the trunk and extremities. The rash is typically preceded by a prodromal phase of cough, coryza, and conjunctivitis, along with the pathognomonic Koplik’s spots on the buccal mucosa. While often self-limited in healthy children, measles remains a major cause of morbidity and mortality, particularly in malnourished or immunocompromised populations.
Globally, measles continues to affect millions of individuals each year, with significant mortality despite widespread vaccination efforts. Although vaccination coverage has improved, outbreaks still occur, especially in low-income countries and in areas affected by conflict or poor healthcare access. Individuals at highest risk include those who are unvaccinated, immunocompromised, pregnant, malnourished, or at extremes of age. Healthcare workers without immunity are also at risk and may contribute to transmission.
The virus spreads via respiratory droplets and initially infects the respiratory mucosa before disseminating through lymphatic and hematogenous routes. It affects multiple organ systems including the skin, conjunctiva, lungs, and gastrointestinal tract. The appearance of the rash corresponds with the host immune response and marks the decline in viral transmissibility. The causative agent is the measles (rubeola) virus, an RNA virus of the Paramyxoviridae family.
Clinically, measles begins with a prodrome of high fever, cough, conjunctivitis, and coryza. Koplik’s spots—small white lesions on the buccal mucosa—appear early and are highly characteristic. This is followed by a red maculopapular rash that starts behind the ears and on the forehead, then spreads downward. The rash typically lasts about five days before fading, sometimes followed by desquamation. In partially immune individuals, atypical and milder presentations may occur.
Diagnosis is primarily clinical, based on characteristic signs and symptoms. Laboratory findings may include leukopenia, T-cell cytopenia, and thrombocytopenia. Serologic testing can confirm diagnosis in atypical cases. Chest imaging may reveal interstitial pneumonitis in severe disease. Viral detection can be performed using immunofluorescence or PCR from respiratory secretions or urine, though this is not always necessary in typical cases.
There is no specific antiviral therapy for measles. Management is mainly supportive, focusing on hydration, fever control, and monitoring for complications. The World Health Organization recommends vitamin A supplementation in children, particularly in developing countries, as it reduces morbidity and mortality. Ribavirin may be considered in severe cases among immunocompromised patients. Antibiotics are reserved only for secondary bacterial infections. Post-exposure prophylaxis with immune serum globulin may prevent or attenuate disease in high-risk individuals.
Prevention is primarily achieved through vaccination with the measles-containing vaccine (commonly the MMR vaccine). The standard schedule includes an initial dose at 12–15 months and a booster at 4–6 years. Vaccination has dramatically reduced global incidence, and there is no evidence linking the vaccine to autism. Certain groups, such as pregnant women and severely immunocompromised individuals, should not receive the live vaccine.
The prognosis is generally excellent in healthy individuals, with lifelong immunity following recovery. However, complications are common in vulnerable populations and may include pneumonia, encephalitis, otitis media, severe diarrhea, and blindness. A rare but fatal long-term complication is subacute sclerosing panencephalitis (SSPE), which can occur years after the initial infection.
Measles is a highly contagious viral disease characterized by fever and a distinctive maculopapular rash that begins on the face and spreads downward to the trunk and extremities. The rash is typically preceded by a prodromal phase of cough, coryza, and conjunctivitis, along with the pathognomonic Koplik’s spots on the buccal mucosa. While often self-limited in healthy children, measles remains a major cause of morbidity and mortality, particularly in malnourished or immunocompromised populations.
Globally, measles continues to affect millions of individuals each year, with significant mortality despite widespread vaccination efforts. Although vaccination coverage has improved, outbreaks still occur, especially in low-income countries and in areas affected by conflict or poor healthcare access. Individuals at highest risk include those who are unvaccinated, immunocompromised, pregnant, malnourished, or at extremes of age. Healthcare workers without immunity are also at risk and may contribute to transmission.
The virus spreads via respiratory droplets and initially infects the respiratory mucosa before disseminating through lymphatic and hematogenous routes. It affects multiple organ systems including the skin, conjunctiva, lungs, and gastrointestinal tract. The appearance of the rash corresponds with the host immune response and marks the decline in viral transmissibility. The causative agent is the measles (rubeola) virus, an RNA virus of the Paramyxoviridae family.
Clinically, measles begins with a prodrome of high fever, cough, conjunctivitis, and coryza. Koplik’s spots—small white lesions on the buccal mucosa—appear early and are highly characteristic. This is followed by a red maculopapular rash that starts behind the ears and on the forehead, then spreads downward. The rash typically lasts about five days before fading, sometimes followed by desquamation. In partially immune individuals, atypical and milder presentations may occur.
Diagnosis is primarily clinical, based on characteristic signs and symptoms. Laboratory findings may include leukopenia, T-cell cytopenia, and thrombocytopenia. Serologic testing can confirm diagnosis in atypical cases. Chest imaging may reveal interstitial pneumonitis in severe disease. Viral detection can be performed using immunofluorescence or PCR from respiratory secretions or urine, though this is not always necessary in typical cases.
There is no specific antiviral therapy for measles. Management is mainly supportive, focusing on hydration, fever control, and monitoring for complications. The World Health Organization recommends vitamin A supplementation in children, particularly in developing countries, as it reduces morbidity and mortality. Ribavirin may be considered in severe cases among immunocompromised patients. Antibiotics are reserved only for secondary bacterial infections. Post-exposure prophylaxis with immune serum globulin may prevent or attenuate disease in high-risk individuals.
Prevention is primarily achieved through vaccination with the measles-containing vaccine (commonly the MMR vaccine). The standard schedule includes an initial dose at 12–15 months and a booster at 4–6 years. Vaccination has dramatically reduced global incidence, and there is no evidence linking the vaccine to autism. Certain groups, such as pregnant women and severely immunocompromised individuals, should not receive the live vaccine.
The prognosis is generally excellent in healthy individuals, with lifelong immunity following recovery. However, complications are common in vulnerable populations and may include pneumonia, encephalitis, otitis media, severe diarrhea, and blindness. A rare but fatal long-term complication is subacute sclerosing panencephalitis (SSPE), which can occur years after the initial infection.
0 Comments
